西酞普兰治疗广泛性焦虑的临床观察

Efficacy and Safety of Citalopram in Patients with Generalized Anxiety Disorder

目的探讨西酞普兰治疗广泛性焦虑症(GAD)的临床疗效和安全性。方法将87例广泛性焦虑患者随机分为研究组(西酞普兰治疗)43例和对照组(氯硝西泮)44例进行对照治疗,疗程6w。结果西酞普兰组HAMA减分平均为12.5±5.8分,对照组减分平均为7.7±6.8分,两组比较差异有统计学意义(t=3.35,P<0.01),西酞普兰治疗14天后及其后各随访点HAMA减分与观察组比较组比较,差异均有统计学意义(P<0.05);西酞普兰治疗组有效率88.4%;对照组有效率37%(χ2=8.22,P<0.01);研究组副反应较对照组少且轻。结论西酞普兰治疗广泛性焦虑起效快、安全有效、副反应低、依从性高。

Objective An open, parallel-group trial was conducted to observe the 6--week efficacy and safety of Citalopram in patient with GAD without associated MDD. Methods A total of 87 patients who met CCMD--3 criteria for GAD were assigned to receive either observed （n= 44） or Citalopram （n=43） for 6 weeks, and changes from baselin in the Hamilton Rating scale for Anxiety total score of two groups and adverse events were compared. Results Response rate in the Citalopram group was 88.4% compared with rate of 37% in the observed group （P〈0. 01） at the end. Citalopram compared with the observed significantly reduced anxiety score measured by the mean changes of HAMA total scale score from week 2 to week 6 （P〈0. 05）. Mean changes of two groups for HAMA from baseline to week 6 were 12.5±5.8 （citalporam） and 7. 7±6.8 （observed） respectively （P〈0. 01）. Citalopram group had significantly fewer side effects. Conclusion Citalopram is effective, rapidly acting, safe for treatment of GAD and may provide an important alternative to currently available anxiolytics.